Intellectual Property
Mar. 1, 2016
Do IPR cases drive down stock prices?
Hedge fund manager Kyle Bass says that an IPR challenge against a single drug costs approximately $1 million. By J. Gregory Sidak and Jeremy O. Skog
Hedge fund manager Kyle Bass, head of Hayman Capital Management, said that he has returned most of the $700 million that he raised from investors as part of a strategy to profit from challenging the validity of patents owned by pharmaceutical companies. In 2015, Bass challenged more than 30 drug patents through the U.S. Patent and Trademark Office's inter partes review (IPR) process, which Congress created in...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In